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The factors affecting noninvasive mechanical ventilation failure
in COPD exacerbations
Feza BACAKOĞLU, Mehmet Sezai TAŞBAKAN, Özen KAÇMAZ BAŞOĞLU, Adnan Tolga ÖZ,
Sedat ÜRKMEZ, Meltem MİDİLLİ, Pervin KORKMAZ EKREN, Alev GÜRGÜN

Aim: To evaluate causes of noninvasive mechanical ventilation (NIMV) failure. The rate of NIMV failure in respiratory
failure due to chronic obstructive pulmonary disease (COPD) exacerbations was reported as 5%-40%.
Materials and methods: The necessity of endotracheal intubation was accepted as NIMV failure. The causes of NIMV
failure were assessed in 54 patients (45 males; mean age: 67.7 ± 11.0 years) treated with NIMV because of COPD
exacerbations and respiratory failure in an intensive care unit (ICU).
Results: There was NIMV failure in 20 patients (37.0%). The rates of hospital-acquired pneumonia and in-hospital
mortality were higher (P = 0.003 and P = 0.002, respectively) and the duration of ICU stay was longer (P < 0.0001) in
patients with NIMV failure. On admission, arterial pH, serum albumin, and Glasgow Coma Scale levels were lower
(P = 0.032, P = 0.024, and P = 0.013, respectively) in the NIMV failure group. Arterial pH was lower (P = 0.039) and
respiratory rate was higher (P = 0.010) after 1 h, and the PaO2/FiO2 rate was lower (P = 0.017) and respiratory and heart
rates were higher (P = 0.002 and P = 0.020, respectively) after 3 h in the NIMV failure group.
Conclusion: The present data strongly suggest that baseline and follow-up clinical and arterial blood gas evaluations can
give important clues about NIMV failure in COPD exacerbations.
Key words: COPD exacerbation, noninvasive ventilation, respiratory failure, treatment failure

KOAH alevlenmesinde noninvaziv mekanik ventilasyon başarısızlığını etkileyen
faktörler
Amaç: Kronik obstrüktif akciğer hastalığı (KOAH) alevlenmesi nedeniyle oluşan solunum yetmezliğinde noninvaziv
mekanik ventilasyon (NİMV) başarısızlığı oranı % 5-40 arasındadır. Bu çalışmanın amacı NİMV başarısızlığının
nedenlerini değerlendirmektir.
Yöntem ve gereç: Endotrakeal entübasyon gerekliliği NİMV başarısızlığı olarak kabul edilmiştir. Yoğun bakım ünitesi
(YBÜ)’nde KOAH alevlenmesi ve solunum yetmezliği nedeniyle tedavi edilen 54 olguda (45’i erkek, ortalama yaş: 67,7
± 11.0) NİMV başarısızlığı değerlendirilmiştir.
Bulgular: 20 olguda (% 37,0) NİMV tedavisi başarısızlığı vardı. Noninvaziv mekanik ventilasyonun başarısız olduğu
olgularda, hastane kökenli pnömoni ve hastane içi mortalite oranları daha yüksek (sırasıyla P = 0,003 ve P = 0,002), yanı
sıra YBÜ kalış süreleri daha uzundu (P < 0.0001). NİMV’nin başarısız olduğu grupta; başvuru anında, arteriyel pH,
serum albumin ve Glasgow koma skalası değerleri daha düşüktü (sırasıyla P = 0,032, P = 0,024 ve P = 0,013). Noninvaziv
mekanik ventilasyonun başarısız olduğu grupta; birinci saatte arteriyel pH daha düşük (P = 0,039) ve solunum sayısı
daha yüksek (P = 0,010), üçüncü saatte ise; PaO2/FiO2 oranı daha düşük (P = 0,017), solunum sayısı ve kalp hızı daha
yüksekti (sırasıyla P = 0,002, P = 0,020).
Sonuç: Başlangıç ve izlemde yapılan klinik ve arteriyel kan gazı değerlendirmelerinin, KOAH alevlenmesinde NİMV
başarısızlığı hakkında önemli ipuçları verebileceği mevcut verilerle kuvvetle desteklenmiştir.
Anahtar sözcükler: KOAH alevlenmesi, noninvaziv ventilasyon, solunum yetmezliği, tedavi başarısızlığı
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Introduction
Noninvasive mechanical ventilation (NIMV) is
more successful than standard medical treatment
alone in respiratory failure, especially in respiratory
acidosis due to chronic obstructive pulmonary disease
(COPD) (1,2). In selected patients, NIMV reduces
endotracheal intubation and prevents invasive
mechanical ventilation (IMV)-related complications,
including hospital-acquired pneumonia (HAP) (310). Noninvasive mechanical ventilation can be
performed effectively and safely in both intensive
care units (ICU) and wards by well-trained teams
(7,9). However, in the guidelines of the American
Thoracic Society and the British Thoracic Society,
NIMV treatment is not recommended for all patients
with respiratory failure. Noninvasive mechanical
ventilation should not be used as a substitute for
intubation and invasive mechanical ventilation when
the latter is clearly more appropriate (11,12).
The rate of NIMV failure in respiratory failure due
to COPD is reported as 5%-40% (3). It is important to
identify the patients most likely benefit from NIMV
treatment. Continuation of NIMV in patients with
treatment failure will delay IMV and increase the
mortality rate. Therefore, the clinical and laboratory
data that can estimate NIMV failure should be
carefully evaluated. The aim of this study was to
investigate the causes of NIMV failure in patients
treated with NIMV because of respiratory failure
associated with COPD exacerbations in an ICU.
Materials and methods
This study was carried out between January 2006
and January 2008 in an 8-bed respiratory ICU in the
chest disease department of a university hospital.
The ICU team consisted of 1 associate professor,
1 chest specialist, 2 registrars, and 3 nurses, and
NIMV treatment has been applied in the ICU since
2002. The results of NIMV treatment were evaluated
retrospectively in hospitalized patients with a COPD
diagnosis, as according to the consensus report of
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) (13), for whom NIMV was applied
due to respiratory failure with acute exacerbations.
Exclusion criteria were as follows: 1) cardiac and
respiratory arrest, 2) severe hemodynamic instability,
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3) encephalopathy, 4) craniofacial pathologies
including surgery and trauma, and 5) severe
gastrointestinal bleeding.
NIMV applications were performed by the
doctors and nurses of the ICU. A portable ventilator
(BiPAP, Moritz biLEVEL, Germany) and oronasal
masks (Respironics, USA; 2 adult sizes: medium
and large) were used for applications. Inspiratory
positive airway pressure (IPAP) of 10 cmH2O and
expiratory positive airway pressure (EPAP) of 4
cmH2O were first applied. The airway pressures were
increased by 1-2 cmH2O each time according to
the arterial blood gas (ABG) results and respiratory
rates, if tolerated by the patient. Maximum airway
pressures were 20 cmH2O for IPAP and 8 cmH2O
for EPAP. Ventilator settings were adjusted on the
basis of continuous oximetry and measurements of
ABG. Clinical signs and ABG levels were determined
at baseline, after 1 and 3 h, and at intervals of 3-6 h
thereafter. The patients were not sedated. Standard
medical treatment (2.5 mg of salbutamol and 500 mg
of ipratropium bromide with a nebulizer every 4-6
h; hourly theophylline infusion of 0.2 mg/kg during
the first 72 h; methylprednisolone at 40 mg/day; lowmolecular-weight prophylactic dose of heparin; and
antibiotics, expectorants, and diuretics, if needed)
and supplemental oxygen administration to achieve a
level of arterial oxygen saturation (by oximetry) above
90% were given in addition to NIMV treatment.
During the first 24 h, NIMV was performed
continuously; it was later reduced progressively
according to the degree of clinical improvement.
Ventilatory support was stopped if the patient
improved and remained stable (pH > 7.35 and SaO2
> 90% with supplemental oxygen). NIMV treatment
was not applied again unless clinical and laboratory
deterioration occurred.
All patients were evaluated only during the period
of ICU stay. Demographic findings, knowledge
about COPD diagnosis and treatment, causes of
exacerbation, and laboratory and ABG analysis data
before NIMV treatment were all recorded. Clinical
findings and ABG analysis data were evaluated
after 1 and 3 h of NIMV treatment. Durations,
complications, and failures of NIMV treatment
were assessed during the follow-up period. The
necessity of endotracheal intubation and IMV was
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called “NIMV failure.” The criteria for endotracheal
intubation included: 1) worsening of the pH and
carbon dioxide tension (PaCO2) in arterial blood
despite NIMV administration, 2) the need to protect
the airways (coma or seizure disorders) or to manage
copious secretions, 3) hemodynamic instability, and
4) agitation and inability to tolerate the mask. The
decision to intubate was made by the same doctor for
all patients.
If NIMV failure developed within the first 2 days,
it was called “early failure,” and if it developed after 2
days, it was called “late failure.” The factors affecting
early and late failure were investigated. Durations
of mechanical ventilation and ICU stay, the rates of
hospital infection, and mortality were compared in
patients with early and late failure.

Table 1. Demographic, clinical, and laboratory characteristics
on admission.
Age (years) (mean ± SD)

67.7 ± 11.0

Sex (male) [n (%)]

45 (83.3%)

Comorbid disease [n (%)] *
CVD
Diabetes mellitus
Others †

30 (55.5%)
9 (16.7%)
18 (33.3%)

Cause of exacerbation [n (%)] ‡
Tracheobronchial infection
Pneumonia
Heart failure
Others #

34 (63.0%)
13 (24.1%)
4 (7.4%)
5 (9.3%)

Respiratory rate (bpm) (mean ± SD)

28.0 ± 7.1

Heart rate (bpm) (mean ± SD)

105.6 ± 22.7

APACHE II (mean ± SD)

17.3 ± 5.0

The study was approved by the local ethics
committee and informed consent was obtained
from the patients or the next of kin.

GCS (mean ± SD)

13.4 ± 2.1

Student’s t-test, NPar tests, and Mann-Whitney
U-tests were used with SPSS 11 for statistical analysis
of the study. The results were expressed as mean ±
standard deviation. Nonparametric values were
compared with chi-square tests. For parameters
affecting NIMV failure, threshold values were
determined, sensitivity and specificity results were
obtained, and receiver operating characteristic
(ROC) curves were drawn. A P-value of less than 0.05
was considered statistically significant.
Results
Included in the study were 54 patients (45 males;
mean age: 67.7 ± 11.0 years) who were hospitalized in
the ICU due to COPD exacerbations and who received
NIMV. The most common cause of exacerbation
was tracheobronchial infection (63.0%). In 13
patients (24.1%), pneumonia was detected, and in 46
patients (85.2%), comorbid diseases were detected.
Demographic features and clinical and laboratory
findings for all patients are summarized in Table 1.
The average IPAP and EPAP levels during
NIMV application were 16.2 ± 1.7 cmH2O and 4.9
± 1.7 cmH2O, respectively. There was no major
complication related to NIMV treatment; the most
common minor complication (70.4%) was skin
necrosis over the nasal bridge.

pH (mean ± SD)

7.23 ± 0.1

PaO2 (mmHg) (mean ± SD)

63.2 ± 19.3

PaCO2 (mmHg) (mean ± SD)

72.4 ± 13.2

PaO2/FiO2 (mean ± SD)

221.4 ± 82.1

Abbreviations: CVD = cardiovascular disease, APACHE = Acute
Physiology and Chronic Health Evaluation, GCS = Glasgow
Coma Scale.
* There were 3 comorbid diseases in 1 patient and 2 comorbid
diseases in 9 patients.
†
Other comorbid diseases: obstructive sleep apnea syndrome
(4 patients), chronic renal failure (3 patients), lung cancer (2
patients), extrapulmonary malignancy (3 patients), chronic
liver disease (2 patients), cerebrovascular disease (2 patients),
obesity (1 patient), obesity-hypoventilation syndrome (1
patient).
‡
The causes of exacerbation were tracheobronchial infections
and heart failure in 2 patients.
#
Other causes of exacerbation: metabolic causes (3 patients),
inappropriate drug use (2 patients).

NIMV was performed successfully in 34 patients
(63.0%), and failure was detected in 20 patients [early
failure in 11 patients (20.3%) and late failure in 9
patients (16.7%)]. HAP was observed in 11 patients
(20.4%) during the follow-up period. The mean
durations of NIMV treatment and ICU stay were 4.5
± 4.6 and 11.6 ± 10.7 days, respectively, and the rate
of mortality was 24.1%.
There was no relationship between NIMV failure
and the demographic features of the patients. The
failure rate of NIMV was higher (53.8% versus 31.7%)
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in patients with pneumonia on admission, but this
difference was not statistically significant.
When the data for NIMV failure and successful
groups on admission were assessed, it was observed
that arterial pH, serum albumin, and Glasgow Coma
Scale (GCS) levels were higher (P = 0.032, P = 0.024,
and P = 0.013, respectively) in the successful group
(Table 2). Follow-up data were also compared in
both groups; the arterial pH was lower (P = 0.039)
and the respiratory rate was higher (P = 0.010) after 1
h, and the PaO2/FiO2 rate was lower (P = 0.017) and
respiratory and heart rates were higher (P = 0.002
and P = 0.020, respectively) after 3 h in the NIMV
failure group when compared to the successful group
(Table 3).
ROC curves of the baseline and follow-up
parameters affecting NIMV failure were drawn, and
their threshold values were determined (Figures 1a1c). Clinical and laboratory features on admission
such as pH < 7.30 (sensitivity 64.7%, specificity 60.0%),
albumin < 3.5 g/dL (sensitivity 71.7%, specificity
65.0%), and GCS < 13 (sensitivity 85.3%, specificity
45.0%) were found to be useful in estimating NIMV
failure. During the follow-up, respiratory rate > 27/

min (sensitivity 60.6%, specificity 60.0%) and pH
< 7.30 (sensitivity 82.4%, specificity 31.6%) after 1
h and respiratory rate > 27/min (sensitivity 57.6%,
specificity 60.0%), heart rate > 100/min (sensitivity
61.8%, specificity 70.0%), and PaO2/FiO2 rate < 200
(sensitivity 73.5%, specificity 36.8%) after 3 h affected
NIMV failure significantly. In addition, the highest
rates of NIMV failure were found in patients with
respiratory rate > 27/min and PaO2/FiO2 rate < 200
after 3 h of NIMV (85.7%) and in patients with GCS
< 13 and pH < 7.30 on admission (80.0%) (Table 4).
The patients with early and late NIMV failure were
compared to those treated successfully. In patients
with early failure, the respiratory rates were higher
after 1 and 3 h (P = 0.045 and P = 0.006, respectively),
and the PaO2/FiO2 rate was lower (P = 0.027) after 3
h. In patients with late failure, respiratory rates were
higher after 1 and 3 h, and heart rate was higher after
3 h (P = 0.037, P = 0.019, and P = 0.015, respectively)
(Table 5).
During the follow-up period, HAP was found to
be higher in patients with NIMV failure than in the
successfully treated group (55.0% versus 8.8%, P =
0.003). The duration of NIMV treatment was longer

Table 2. The comparison of clinical and laboratory characteristics on admission
according to the success of noninvasive mechanical ventilation treatment.

Parameters

*

Respiratory rate (bpm)
Heart rate (bpm)

NIMV
success
(n = 34)

NIMV
failure
(n = 20)

27.2 ± 6.6

29.5 ± 7.8

P-value
NS

103.5 ± 22.3

109.1 ± 23.6

NS

APACHE II

16.9 ± 4.9

18.0 ± 5.0

NS

GCS

13.9 ± 1.7

12.5 ± 2.5

0.013

pH

7.32 ± 0.1

7.28 ± 0.1

0.032

PaO2 (mmHg)

62.3 ± 21.2

64.8 ± 15.8

NS

PaCO2 (mmHg)

71.1 ± 10.9

74.7 ± 16.6

NS

PaO2/FiO2

228.1 ± 86.8

209.9 ± 74.2

NS

CRP (mg/dL)

7.9 ± 10.8

11.8 ± 10.4

NS

Albumin (g/dL)

3.6 ± 0.5

3.3 ± 0.5

0.024

Abbreviations: NIMV = noninvasive mechanical ventilation, APACHE = Acute
Physiology and Chronic Health Evaluation, GCS = Glasgow Coma Scale, CRP =
C-reactive protein, NS = nonsignificant.
*
Data given as mean ± SD.
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Table 3. The comparison of clinical and laboratory characteristics after 1 and 3 h
according to the success of noninvasive mechanical ventilation treatment.
NIMV
success
(n = 34)

NIMV
failure
(n = 20)

After 1 h
Respiratory rate (bpm)
Heart rate (bpm)
pH
PaO2 (mmHg)
PaCO2 (mmHg)
PaO2/FiO2

24.8 ± 6.8
98.6 ± 22.4
7.36 ± 0.1
67.4 ± 16.8
65.5 ± 11.0
227.8 ± 71.7

30.1 ± 7.2
110.7 ± 22.0
7.31 ± 0.1
70.1 ± 24.7
68.3 ± 14.2
222.2 ± 76.7

0.010
NS
0.039
NS
NS
NS

After 3 h
Respiratory rate (bpm)
Heart rate (bpm)
pH
PaO2 (mmHg)
PaCO2 (mmHg)
PaO2/FiO2

25.9 ± 6.8
97.9 ± 19.0
7.37 ± 0.1
63.3 ± 10.5
61.8 ± 11.8
237.3 ± 56.8

33.0 ± 8.7
111.7 ± 22.4
7.34 ± 0.1
60.3 ± 12.5
65.3 ± 14.4
199.4 ± 47.1

0.002
0.020
NS
NS
NS
0.017

Parameters

*

P-value

Abbreviations: NIMV = noninvasive mechanical ventilation, NS = nonsignificant.
Data given as mean ± SD.

*

in patients treated successfully with NIMV (5.3 ± 5.1
versus 3.0 ± 3.0 days, P < 0.05), whereas the duration
of ICU stay was longer in the NIMV failure group
(19.5 ± 12.9 versus 6.9 ± 5.3 days, P < 0.0001). There
was in-hospital mortality in 10 patients (50.0%) with
NIMV failure, and only 3 of 34 patients (8.8%, P =
0.002) in the successfully treated group died.
Discussion
In the present study, NIMV treatment was
successful in 63.0% of patients with respiratory
failure due to COPD exacerbations, whereas
treatment failure was observed in 20 patients (early
failure in 11, late failure in 9). When admission
data were compared between the NIMV failure and
success groups, arterial pH, serum albumin, and GCS
levels were higher in the successful group. During
the follow-up, it was found that the arterial pH was
higher and the respiratory rate was lower after 1 h,
while the PaO2/FiO2 rate was higher and respiratory
and heart rates were lower after 3 h in the successful
group. The rates of in-hospital mortality and HAP
were observed to be higher and the duration of ICU
stay was longer in the NIMV failure group.

The rate of success of NIMV in respiratory
failure due to COPD exacerbations ranges from
60% to 95%. Confalonieri et al. (14) showed that
NIMV application in acute exacerbations of COPD
was effective in 77.1% of 1033 patients. Similarly,
Antonio et al. (15) successfully treated 34 of 44
episodes (77.0%) of chronic airflow limitation with
acute hypercapnic respiratory failure with NIMV,
and endotracheal intubation was avoided. In another
study carried out in our clinic, NIMV was useful and
IMV treatment was not required in 28 of 38 patients
(73.7%) (16). In the present study, NIMV treatment
was successful in 63.0% of patients with respiratory
failure due to COPD exacerbations.
The failure of NIMV was evaluated as early
failure or late failure and the causes of failure were
investigated in certain studies. Moretti et al. (17)
applied NIMV treatment in 136 patients with COPD
acute exacerbations, and they determined late failure
in 31 patients (23%). Carratu et al. (18) evaluated
NIMV success in 122 patients with respiratory failure
due to COPD exacerbations, and they observed early
failure in 13 patients (10.7%) and late failure in 10
patients (8.2%). We found early failure in 11 patients
107
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b. First hour of NIMV;
a . Baseline

Respiratory rate (AUC = 0.696, CI=0.552 -0.841 )

pH (AUC= 0.663, CI=0.505-0.821)

pH (AUC= 0.667, CI=0.510-0.825)
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c. Third hour of NIMV;
Respiratory rate (AUC = 0.731, CI=0.590 -0.872)
Heart rate (AUC=

0.697, CI=0.543 -0.8 51) ,

PaO 2/FiO 2 (AUC= 0.696, CI=0.550 -0.842).

Figure 1. ROC curves, area under the curves (AUC), and confidence intervals (CI) of the factors affecting success rates a) at the baseline,
b) after 1 h, and c) after 3 h of noninvasive mechanical ventilation treatment (NIMV).

(20.3%) and late failure in 9 patients (16.7%). The
rates of failure in our study were similar to other rates
found in the literature.
It is important to elucidate the risk factors for
NIMV failure on admission. Levels of GCS < 11,
108

Acute Physiology and Chronic Health Evaluation II
(APACHE II) scores > 28, respiratory rate > 29/min,
and pH < 7.25 at baseline were found to be related in
more than 70% of NIMV failure cases (14). Antonio
et al. (15) showed that the level of consciousness was
the only factor affecting NIMV success. In another
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Table 4. The effect of baseline and follow-up clinical and laboratory characteristics on
noninvasive mechanical ventilation failure.
NIMV
failure rate (%)

Parameters
Baseline
GCS < 13 and pH < 7.30
GCS < 13 and albumin < 3.5 g/dL
Albumin < 3.5 g/dL and pH < 7.30

80.0
63.6
53.8

After 1 h
Respiratory rate > 27/min and pH < 7.30

50.0

After 3 h
Respiratory rate > 27/min and PaO2/FiO2 < 200
Heart rate > 100/min and PaO2/FiO2 < 200
Respiratory rate > 27/min and heart rate > 100/min

85.7
66.7
60.0

Abbreviations: NIMV = noninvasive mechanical ventilation, GCS = Glasgow Coma
Scale.

Table 5. The comparison of clinical and laboratory characteristics after 1 and 3 h according to early and
late noninvasive mechanical ventilation failure.
NIMV
success
(n = 34)

NIMV
early failure
(n = 11)

NIMV
late failure
(n = 9)

After 1 h
Respiratory rate (bpm)
Heart rate (bpm)
pH
PaO2 (mmHg)
PaCO2 (mmHg)
PaO2/FiO2

24.8 ± 6.8
98.6 ± 22.4
7.36 ± 0.1
67.4 ± 16.8
65.5 ± 11.0
227.8 ± 71.7

30.1 ± 8.8 *
108.6 ± 22.2
7.31 ± 0.1
73.1 ± 28.8 †
69. 8 ± 14.7
232.5± 91

30.1 ± 5.3 *
113.2 ± 22.8
7.30 ± 0.1
65.9 ± 18.8
66.1 ± 14.1
207.8 ± 53.7

After 3 h
Respiratory rate (bpm)
Heart rate (bpm)
pH
PaO2 (mmHg)
PaCO2 (mmHg)
PaO2/FiO2

25.9 ± 6.8
97.9 ± 19.0
7.37 ± 0.1
63.3 ± 10.5
61.8 ± 11.8
237.3 ± 56.8

33.7 ± 10.1 ‡
107.7 ± 23.3
7.32 ± 0.1
61.6 ± 11.1
69.3 ± 16.4
190.4 ± 29.6 #

32.1 ± 7.2 †
116.6 ± 21.7 ‡
7.35 ± 0.1
58.9 ± 14.4
60.9 ± 11.3
209.4 ± 61.6

Parameters*

Abbreviation: NIMV = noninvasive mechanical ventilation.
Comparison of success and early failure: *P = 0.045, †P = 0.033, ‡P = 0.006, #P = 0.027.
Comparison of success and late failure: *P = 0.037, †P = 0.019, ‡P = 0.015.
*
Data given as mean ± SD.
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study, poor consciousness was also related to NIMV
failure (19). In 111 patients with acute hypercapnic
respiratory failure (COPD in 43 patients), high
APACHE II scores and high heart rates on admission
were detected as estimated parameters of NIMV
success (20). In our previous study carried out in
our ICU, high APACHE II scores on admission were
determined as a factor predicting NIMV outcomes
(16). When baseline data of NIMV failure and
success groups were assessed in this study, arterial
pH, serum albumin, and GCS levels were higher in
the successful group. Similar to other investigations,
arterial pH and GCS were the parameters affecting
the success of NIMV. It was reported that serum
albumin levels had no effect on NIMV results (17).
However, in our study, mean serum albumin level
was found to be lower in patients with NIMV failure
(3.3 g/dL versus 3.6 g/dL). Therefore, future studies
evaluating the relationship between serum albumin
level and NIMV success are needed. The evaluation of
baseline characteristics together showed that NIMV
failure was more common in patients with GCS < 13
and pH < 7.30 (80.0%).
The presence of pneumonia at the beginning of
treatment also affected NIMV success (18). In our
study, the failure rate of NIMV was higher in patients
with pneumonia on admission, but the difference
was not statistically significant.
The effect of follow-up findings on NIMV failure
should also be evaluated. Improvements in the level
of consciousness and in values of pH and PaCO2 after
1 h were found to be related to treatment success
(15). The risk of NIMV failure for a pH value of less
than 7.25 after 2 h of treatment was determined to be
90.0% (14). In our study, lower arterial pH and higher
respiratory rates were detected after 1 h, and a lower
PaO2/FiO2 rate and higher respiratory and heart rates
were found after 3 h in the NIMV failure group. The
most important follow-up parameter affecting NIMV
success was the respiratory rate. The assessment of
follow-up characteristics together indicated that the
highest rates for NIMV failure were found in patients
with respiratory rate > 27/min and PaO2/FiO2 < 200
(85.7%) and in patients with heart rate > 100/min
and PaO2/FiO2 < 200 (66.7%).
The evaluations for early and late failure of NIMV
were also performed separately. Moretti et al. (17)
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reported that late failure of NIMV was related to the
comorbid diseases and low arterial pH on admission.
In another study (18), higher values of APACHE II
scores and respiratory and heart rates, and lower
values for GCS scores, PaO2/FiO2 rate, and arterial pH
values at baseline, were found to be the characteristics
for early failure. In addition, accompanied pneumonia
and cardiac and renal diseases in patients with early
failure, and accompanied cardiac and renal diseases
in patients with late failure, were significantly
more frequent. In our study, it was found that the
respiratory rate and PaO2 were higher after 1 h, and
the respiratory rate was higher and PaO2/FiO2 was
lower after 3 h in the early failure group. The value of
PaO2 was unexpectedly higher in patients with early
failure. It was thought that administration of more
supplemental oxygen than required after 1 h could be
the explanation for this finding. Therefore, use of the
PaO2/FiO2 rate might be more appropriate. Respiratory
rate after 1 h and both respiratory and heart rates after
3 h were higher in patients with late failure. Although
it was demonstrated that comorbidity, especially
cardiovascular disease, decreased the success rate
of NIMV in COPD exacerbations (15,18,19,21),
comorbid diseases in our study did not affect NIMV
results.
It was reported that the risk of HAP was lower
in patients treated with NIMV compared to IMV
patients (9,10). In our study, the rate of HAP in the
NIMV success group was also lower (8.8% versus
50.0%). In addition, the duration of ICU stay was
longer (19.5 ± 12.9 versus 6.9 ± 5.3 days) in the
NIMV failure group, similar to the results of Phua
et al. (20). Endotracheal intubation due to NIMV
failure and IMV-related complications such as HAP
prolong the duration of ICU stay and increase the
cost of treatment.
Moretti et al. (17) detected a mortality rate of
53.0% in patients treated with IMV because of
NIMV failure. They found a mortality rate of 92.0% if
NIMV treatment continued in spite of failure. It was
concluded that the mortality rate increased in patients
with NIMV failure, especially in those treated with
NIMV in spite of failure. In our study, in-hospital
mortality was detected in 50.0% of patients with
NIMV failure, whereas only 8.8% of the successfully
treated patients died.

F. BACAKOĞLU, M. S. TAŞBAKAN, Ö. KAÇMAZ BAŞOĞLU, A. T. ÖZ, S. ÜRKMEZ, M. MİDİLLİ, P. KORKMAZ EKREN, A. GÜRGÜN

There are some limitations of this study. First,
the number of cases is small. Therefore, multiple
regression analysis could not be carried out. Second,
this study is retrospective and not comparative.
Despite these limitations, we have been
performing NIMV since 2002 and wanted to present
the experience of our center. We have found that
arterial pH, serum albumin, and GCS on admission
are important factors that affect the success of
NIMV, similar to other results in the literature. We
particularly emphasize that the serum albumin level
is a prognostic factor in predicting NIMV success. In
our study, unlike previous studies in the literature,
the presence of comorbid conditions did not affect
the NIMV response.

Conclusion
In the present study, use of NIMV avoided
endotracheal intubation in 63.0% of patients with
respiratory failure due to COPD exacerbations,
whereas NIMV was not useful in 11 patients in the
early period and IMV was required in 9 patients in
the late period. It was thought that clinical, laboratory,
and ABG analysis data on admission and after 3 h gave
important clues about NIMV success. The evaluation
of baseline and follow-up data may be useful in
determining whether to begin NIMV treatment in
respiratory failure due to COPD exacerbation, and it
may prevent the delay of intubation in patients with
high probabilities of NIMV failure.
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